ARS Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
ARS Pharmaceuticals has a total shareholder equity of $223.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $227.6M and $3.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$223.63m |
Equity | US$223.87m |
Total liabilities | US$3.72m |
Total assets | US$227.58m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: SPRY's short term assets ($226.2M) exceed its short term liabilities ($3.7M).
Long Term Liabilities: SPRY has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SPRY is debt free.
Reducing Debt: SPRY had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPRY has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SPRY has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 59.3% each year